AI assistant
Edgewise Therapeutics, Inc. — Director's Dealing 2021
Mar 26, 2021
31829_dirs_2021-03-25_d527c963-f069-43c3-a29e-8c36fed70709.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-25
Reporting Person: Derakhshan Behrad (Chief Business Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.71 | 2030-09-21 | Common Stock (288163) | Direct | |
| Stock Option (Right to Buy) | $1.93 | 2030-12-15 | Common Stock (155017) | Direct |
Footnotes
F1: 1/4th of the shares subject to the option will become vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.
F2: 1/48th of the shares subject to the option became vested and exercisable on January 3, 2021 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.